Healthcare · Profile from Healthcare Research Companion
Labcorp Holdings Inc.
The Burlington, North Carolina, laboratory giant formed in 1995 by merging National Health Laboratories with Roche Biomedical Laboratories. For two decades it was the second of America's two national labs behind Quest; buying Covance for ~$6.2bn in 2015 made it the larger company by total revenue and, for eight years, one of the world's biggest drug-development contract research organisations. It won a decade-long exclusive with UnitedHealthcare (2007–17), built specialty testing through deals such as Genzyme Genetics, ran millions of COVID-19 tests and the first FDA-authorised home collection kit, then reversed course by spinning off its clinical development business as Fortrea in 2023. Since then it has refocused on diagnostics and lab services for drug makers, buying hospital outreach programmes and the assets of distressed labs.
At a glance
- Founded
- 1995, via merger (effective 28 April 1995) of National Health Laboratories (La Jolla, California) and Roche Biomedical Laboratories (Burlington, North Carolina), whose roots go back to Biomedical Laboratories, founded by the Powell brothers in a Burlington hospital basement in 1969
- Founders
- Formed by Roche and NHL; predecessor founded by Dr. James Powell and John Powell (Biomedical Laboratories, 1969)
- Headquarters
- Burlington, North Carolina
- Ownership / structure
- Public company, NYSE: LH; since 17 May 2024 the listed parent is Labcorp Holdings Inc., a new holding company above Laboratory Corporation of America Holdings (same ticker); S&P 500
- Leadership (2026)
- Adam Schechter, chairman and CEO (CEO since 1 November 2019, formerly Merck); Julia Wang, CFO (since 2 December 2024, formerly CFO of BeiGene)
- Segment and buyer
- Diagnostics Laboratories (routine, specialty and consumer testing) and Biopharma Laboratory Services (central labs and early development for drug makers). Diagnostics payers are commercial plans, Medicare, Medicaid, patients and client institutions; biopharma customers pay under service contracts
- Scale
- 2025 revenue $13.95bn (2024: $13.01bn), of which Diagnostics ~$10.88bn and Biopharma Laboratory Services ~$3.10bn; adjusted EPS $16.44; free cash flow $1.21bn (reported). Q3 2026 revenue $3.81bn (+6.9%); 2026 guidance raised in October 2026 to $14.78–14.89bn and adjusted EPS $18.30–18.70 (reported). Roughly 70,000 employees (verify)
- Capital / market cap
- Self-funded; investment-grade debt; market cap ~$20bn+ in 2025–26 (verify current level)
- Signature moves (incl. failures)
- NHL–Roche Biomedical merger (1995); UnitedHealthcare exclusive (2007–17); Genzyme Genetics (2010); Covance (2015); AMCA vendor breach (2019); COVID-19 testing and Pixel home kit (2020); Fortrea spin-off (2023); Invitae, BioReference and hospital outreach deals (2024–26)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
1995
Roche Biomedical Merger
Merger
2007
UnitedHealthcare Exclusive Contract
Payer contract (exclusive network)
2010
Genzyme Genetics Acquisition
Acquisition
2015
Covance Acquisition
Acquisition
2019
AMCA Data Breach
Data breach (vendor)
2020
Covid Testing and Pixel Home Kit
Demand shock / launch
2023
Fortrea Spin Off
Spin-off / strategic reversal
2024
Invitae and Outreach Deals
Acquisitions